UBS Group’s NxStage Medical Inc. NXTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-893,856
| Closed | -$25.6M | – | 8545 |
|
|
2018
Q4 | $25.6M | Sell |
893,856
-104,133
| -10% | -$2.96M | 0.01% | 922 |
|
|
2018
Q3 | $27.8M | Buy |
997,989
+15,673
| +2% | +$441K | 0.01% | 996 |
|
|
2018
Q2 | $27.4M | Buy |
982,316
+483,274
| +97% | +$13M | 0.01% | 979 |
|
|
2018
Q1 | $12.4M | Sell |
499,042
-202,409
| -29% | -$4.92M | 0.01% | 1516 |
|
|
2017
Q4 | $17M | Buy |
701,451
+209,495
| +43% | +$5.52M | 0.01% | 1302 |
|
|
2017
Q3 | $13.6M | Buy |
491,956
+470,693
| +2,214% | +$12.6M | 0.01% | 1378 |
|
|
2017
Q2 | $533K | Buy |
21,263
+493
| +2% | +$12.2K | ﹤0.01% | 4078 |
|
|
2017
Q1 | $557K | Buy |
20,770
+2,035
| +11% | +$56.2K | ﹤0.01% | 3958 |
|
|
2016
Q4 | $491K | Buy |
18,735
+270
| +1% | +$6.68K | ﹤0.01% | 4138 |
|
|
2016
Q3 | $461K | Sell |
18,465
-4,598
| -20% | -$107K | ﹤0.01% | 3969 |
|
|
2016
Q2 | $500K | Sell |
23,063
-10,128
| -31% | -$181K | ﹤0.01% | 3888 |
|
|
2016
Q1 | $498K | Sell |
33,191
-5,091
| -13% | -$85.3K | ﹤0.01% | 3783 |
|
|
2015
Q4 | $838K | Buy |
38,282
+24,425
| +176% | +$455K | ﹤0.01% | 3547 |
|
|
2015
Q3 | $219K | Sell |
13,857
-4,869
| -26% | -$78.1K | ﹤0.01% | 4558 |
|
|
2015
Q2 | $267K | Sell |
18,726
-4,519
| -19% | -$76.5K | ﹤0.01% | 4625 |
|
|
2015
Q1 | $402K | Sell |
23,245
-1,971
| -8% | -$34.8K | ﹤0.01% | 4322 |
|
|
2014
Q4 | $452K | Buy |
+25,216
| New | +$406K | ﹤0.01% | 4294 |
|
Other funds holding NXTM
UBS Group's NXTM Position: Q1 2019 in Review
UBS Group sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 893,856 shares — an estimated $25.6M sold.
UBS Group first reported a position in NXTM in Q4 2014 and held it in 17 quarters. The position peaked at $27.8M in Q3 2018. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.
- UBS Group reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 893,856 NxStage Medical Inc. shares in Q1 2019, an estimated $25.6M.
- UBS Group first reported a position in NxStage Medical Inc. in Q4 2014 and held it in 17 quarters.
- UBS Group's NxStage Medical Inc. position peaked at $27.8M in Q3 2018.
- 1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.